|
Determinants of Outcome of Compensated Hepatitis C
Virus-Related Cirrhosis
References
1. Feray C, Gigou M, Samuel D, Paradis V, David MF, Lemonnier C,
et al. The course of hepatitis C virus infection after liver
transplantation. HEPATOLOGY 1994; 20: 1137-1143[Abstract].
2. Seef LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ,
Iber FL, et al. Long-term mortality after transfusion-associated
Non-A, Non-B hepatitis. N Engl J Med 1992; 327:
1906-1911[Medline].
3. Koretz RL, Abey H, Coleman E, Gitnick G. Non-A, non-B
post-transfusion hepatitis: looking back in the second decade. Ann
Intern Med 1993; 119: 110-115[Medline].
4. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH,
Melpolder JJ, Alter HJ. Long-term clinical and histopathological
follow-up of chronic posttransfusion hepatitis. HEPATOLOGY 1991;
14: 969-74[Abstract].
5. Hopf U, Küther D, Stemerowicz R, Stemerowicz R, Lobeck
H, Lüdtke-Handjery A, et al. Long-term follow-up of
posttransfusion and sporadic chronic hepatitis non-A, non-B and
frequency of circulating antibodies to hepatitis C virus (HCV). J
Hepatol 1990; 10: 69-76[Medline].
6. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero
ML, et al. Long-term follow-up of non-A, non-B (type C)
post-transfusion hepatitis. J Hepatol 1992; 16:
273-281[Medline].
7. Tong JM, El-Farra NS, Reikes AR, Co RL. Clinical outcomes
after transfusion-associated hepatitis C. N Engl J Med 1995; 332:
1463-1466[Medline].
8. Colombo M, De Franchis R, Del Ninno E, Sangiovanni A, De
Fazio C, Tomasini M, et al. Hepatocellular carcinoma in italian
patients with cirrhosis. N Engl J Med 1991; 325:
675-680[Medline].
9. Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, et
al. A multivariate analysis of risk factors for hepatocellular
carcinogenesis: a prospective observation of 795 patients with
viral and alcoholic cirrhosis. HEPATOLOGY 1993; 18:
47-53[Abstract].
10. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura
T, et al. Risk factors for hepatocellular carcinoma among patients
with chronic liver disease. N Engl J Med 1993; 328:
1797-1801[Medline].
11. Cottone M, Turri M, Caltagirone M, Parisi P, Orlando A,
Fiorentino G, et al. Screening for hepatocellular carcinoma in
patients with Child's A cirrhosis: an 8-years prospective study by
ultrasound and alphafetoprotein. J Hepatol 1994; 21:
1029-1034[Medline].
12. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P,
Bréchot C, the Collaborative Study Group. Hepatitis C virus
type 1b (II) infection in France and Italy. Ann Intern Med 1995;
122: 161-168[Medline].
13. Mita E, Hayashi N, Kanazawa Y, Hagiwara H, Ueda K, Kasahara
A, et al. Hepatitis C virus genotype and RNA titer in the
progression of type C chronic liver disease. J Hepatol 1994; 21:
468-473[Medline].
14. Pozzato G, Kaneko S, Morreti M, Saveria Croce L, Franzin F,
Unoura M, et al. Different genotypes of hepatitis C virus are
associated with different severity of liver disease. J Med Virol
1994; 43: 291-296[Medline].
15. Yamada M, Kakumu S, Yoshioka K, Higashi Y, Tanaka K,
Ishikawa T, et al. Hepatitis C virus genotypes are not responsible
for development of serious liver disease. Dig Dis Sci 1994; 39:
234-239[Medline].
16. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T,
Nakajima S, et al. Randomised trial of effects of interferon-alfa
on incidence of hepatocellular carcinoma in chronic active
hepatitis C with cirrhosis. Lancet 1995; 346:
1051-1055[Medline].
17. Mazzela G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta
A, et al. Alpha interferon treatment may prevent hepatocellular
carcinoma in HCV-related liver cirrhosis. J Hepatol 1996; 24:
141-147[Medline].
18. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B,
Van Heuverswyn H, et al. Typing of hepatitis C virus isolates and
characterization of new subtypes using a line probe assay. J Gen
Virol 1993; 74: 1093-1102[Medline].
19. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW,
Brechot C, et al. A proposed system for the nomenclature of
hepatitis C viral genotypes. HEPATOLOGY 1994; 19:
1321-1324[Medline].
20. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz
N, et al. Formulation and application of a numerical scoring system
for assessing histological activity in asymptomatic chronic active
hepatitis. HEPATOLOGY 1981; 1: 431-435[Abstract].
21. Kaplan EL, Meier P. Non parametric estimation for incomplete
observation. J Am Stat Assoc 1958; 53: 457-481.
22. Cox DR. Regression models and lifes tables. J R Stat Soc B
1972; 34: 248-275.
23. Serfaty L, Chazouillères O, Poujol-Robert A,
Morand-Joubert L, Dubois C, Chrétien Y, et al. Risk factors
for liver cirrhosis in patients with chronic HCV infection: results
of a case control study. HEPATOLOGY 1997; 26:
776-779[Abstract].
24. Pagliaro L, Craxi A, Camma C, Tine F, Di Marco V, Lo Iacono
O, et al. Interferon-alpha for chronic hepatitis C: an analysis of
pretreatment clinical predictors of response. HEPATOLOGY 1994; 19:
820-828[Abstract].
25. Camps J, Crisostomo S, Garcia-Granero M, Riezu-Boj JI,
Civeira MP, Prieto J. Prediction of the response of chronic
hepatitis C to interferon alfa: a statistical analysis of
pretreatment variables. Gut 1993; 34: 1714-1717[Abstract].
26. Serfaty L, Giral P, Loria A, Andréani T, Legendre C,
Poupon R. Factors predictive of the response to interferon in
patients with chronic hepatitis C. J Hepatol 1994; 21:
12-17[Medline].
27. Fattovich G, Giustina G, Degos F, Tremolada F, Diaodati G,
Almasio P, et al. Morbidity and mortality in compensated cirrhosis
type C: a retrospective follow-up study of 384 patients.
Gastroenterology 1997; 112: 463-472[Abstract].
28. Castilla A, Prieto J, Fausto N. Transforming growth factors
b 1 and alfa in chronic liver disease. Effects of interferon
therapy. N Engl J Med 1991; 324: 933-940[Medline].
29. Manabe M, Chevallier M, Chossegros P, Causse X, Guerret S,
Trepo C, et al. Interferon-alfa 2b therapy reduces liver fibrosis
in chronic non-A, non-B hepatitis: a quantitative histological
evolution. HEPATOLOGY 1993; 18: 1344-1349[Abstract].
30. Camps J, Castilla A, Ruiz J, Civeira MP, Prieto J.
Randomised trial of lymphoblastoïd alfa-interferon in chronic
hepatitis C. Effect on inflammation, fibrogenesis and viremia. J
Hepatol 1993; 17: 390-396[Medline].
31. Jimenez SA, Freundlich B, Rosenbloom J. Selective inhibition
of human diploïd fibroblast collagen synthesis by interferon.
J Clin Invest 1984; 74: 1112-1116[Medline].
32. Mavier P, Préaux AM, Charlotte F, Dhumeaux D,
Rosenbaum J. Effects of alpha- and gamma-interferons on the growth
and collagen synthesis of human hepatic myofibroblastic Ito cells
[Abstract]. HEPATOLOGY 1992; 16: 185A.
33. Saibara T, Maeda T, Miyazaki M, Onishi S, Yamamoto Y.
Depressed immune function in patients with cirrhosis before
emergence of hepatocellular carcinoma. HEPATOLOGY 1993; 18:
315-319[Abstract].
34. Baron S, Tyring SK, Fleischmann WR, Coppenhauer DH, Niesel
DW, Klimpel GR. The interferons. Mechanisms of action and clinical
applications. JAMA 1991; 266: 1375-1383[Medline].
35. Sing RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler
IJ. Interferon alfa and down-regulate the expression of basic
fibroblast growth factor in human carcinoma. Proc Natl Acad Sci U S
A 1995; 92: 4562-4566[Medline].
36. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a
therapy for life- threatening hemangiomas of infancy. N Engl J Med
1992; 326: 1456[Medline].
Return To
Article
Copyright © 1998 by the American Association for the Study
of Liver Diseases.
|
